Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers

Lorenza Rimassa, Armando Santoro, Bruno Daniele, Domenico Germano, Antonio Gasbarrini, Stefania Salvagni, Gianluca Masi, Giovanni Abbadessa, Maria Lamar, Terri Goldberg, Camillo Porta

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most common cause of cancer-related death worldwide. The evidence-based therapy for advanced HCC that is unsuitable for locoregional treatment is limited to sorafenib, with no second-line option available. This article focuses on the development of the MET inhibitor tivantinib in HCC as a promising treatment option for patients who failed sorafenib. A randomized, placebo-controlled phase II study showed activity of tivantinib in patients with high MET expression. Based on these results, the METIV-HCC phase III study in second-line treatment for MET-high patients was initiated to demonstrate the survival advantage of tivantinib compared to placebo.

Original languageEnglish
Pages (from-to)139-143
Number of pages5
JournalTumori
Volume101
Issue number2
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Hepatocellular Carcinoma
Placebos
Therapeutics
Survival
ARQ 197
sorafenib
Neoplasms

Keywords

  • Hepatocellular carcinoma
  • MET
  • Second-line treatment
  • Tivantinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers. / Rimassa, Lorenza; Santoro, Armando; Daniele, Bruno; Germano, Domenico; Gasbarrini, Antonio; Salvagni, Stefania; Masi, Gianluca; Abbadessa, Giovanni; Lamar, Maria; Goldberg, Terri; Porta, Camillo.

In: Tumori, Vol. 101, No. 2, 01.03.2015, p. 139-143.

Research output: Contribution to journalArticle

Rimassa, L, Santoro, A, Daniele, B, Germano, D, Gasbarrini, A, Salvagni, S, Masi, G, Abbadessa, G, Lamar, M, Goldberg, T & Porta, C 2015, 'Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers', Tumori, vol. 101, no. 2, pp. 139-143. https://doi.org/10.5301/tj.5000217
Rimassa, Lorenza ; Santoro, Armando ; Daniele, Bruno ; Germano, Domenico ; Gasbarrini, Antonio ; Salvagni, Stefania ; Masi, Gianluca ; Abbadessa, Giovanni ; Lamar, Maria ; Goldberg, Terri ; Porta, Camillo. / Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers. In: Tumori. 2015 ; Vol. 101, No. 2. pp. 139-143.
@article{597d0398fb39453cbb7993d3c338890d,
title = "Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers",
abstract = "In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most common cause of cancer-related death worldwide. The evidence-based therapy for advanced HCC that is unsuitable for locoregional treatment is limited to sorafenib, with no second-line option available. This article focuses on the development of the MET inhibitor tivantinib in HCC as a promising treatment option for patients who failed sorafenib. A randomized, placebo-controlled phase II study showed activity of tivantinib in patients with high MET expression. Based on these results, the METIV-HCC phase III study in second-line treatment for MET-high patients was initiated to demonstrate the survival advantage of tivantinib compared to placebo.",
keywords = "Hepatocellular carcinoma, MET, Second-line treatment, Tivantinib",
author = "Lorenza Rimassa and Armando Santoro and Bruno Daniele and Domenico Germano and Antonio Gasbarrini and Stefania Salvagni and Gianluca Masi and Giovanni Abbadessa and Maria Lamar and Terri Goldberg and Camillo Porta",
year = "2015",
month = "3",
day = "1",
doi = "10.5301/tj.5000217",
language = "English",
volume = "101",
pages = "139--143",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? the experience of Italian centers

AU - Rimassa, Lorenza

AU - Santoro, Armando

AU - Daniele, Bruno

AU - Germano, Domenico

AU - Gasbarrini, Antonio

AU - Salvagni, Stefania

AU - Masi, Gianluca

AU - Abbadessa, Giovanni

AU - Lamar, Maria

AU - Goldberg, Terri

AU - Porta, Camillo

PY - 2015/3/1

Y1 - 2015/3/1

N2 - In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most common cause of cancer-related death worldwide. The evidence-based therapy for advanced HCC that is unsuitable for locoregional treatment is limited to sorafenib, with no second-line option available. This article focuses on the development of the MET inhibitor tivantinib in HCC as a promising treatment option for patients who failed sorafenib. A randomized, placebo-controlled phase II study showed activity of tivantinib in patients with high MET expression. Based on these results, the METIV-HCC phase III study in second-line treatment for MET-high patients was initiated to demonstrate the survival advantage of tivantinib compared to placebo.

AB - In the last decades the management of hepatocellular carcinoma (HCC) has undergone significant changes following the introduction of novel therapies such as sorafenib, which have improved patient survival. Nevertheless, HCC is still the third most common cause of cancer-related death worldwide. The evidence-based therapy for advanced HCC that is unsuitable for locoregional treatment is limited to sorafenib, with no second-line option available. This article focuses on the development of the MET inhibitor tivantinib in HCC as a promising treatment option for patients who failed sorafenib. A randomized, placebo-controlled phase II study showed activity of tivantinib in patients with high MET expression. Based on these results, the METIV-HCC phase III study in second-line treatment for MET-high patients was initiated to demonstrate the survival advantage of tivantinib compared to placebo.

KW - Hepatocellular carcinoma

KW - MET

KW - Second-line treatment

KW - Tivantinib

UR - http://www.scopus.com/inward/record.url?scp=84930581374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930581374&partnerID=8YFLogxK

U2 - 10.5301/tj.5000217

DO - 10.5301/tj.5000217

M3 - Article

VL - 101

SP - 139

EP - 143

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -